Celecoxib: A novel treatment for lung cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 5, 2004, Pages 725-734

  Abou Issa, Hussein ^a   Alshafie, Galal ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Celecoxib; Combination therapy; Cyclooxygenase; Non small cell lung cancer; Nonsteroidal anti inflammatory agents; Prostaglandins; Radiation therapy; Selective COX 2 inhibitor

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DOCETAXEL; ERLOTINIB; ETORICOXIB; GEFITINIB; GEMCITABINE; IBUPROFEN; IRINOTECAN; LUMIRACOXIB; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; PACLITAXEL; ROFECOXIB; TAXANE DERIVATIVE; TILMACOXIB; UNCLASSIFIED DRUG; VALEDOCOXIB; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; IN VITRO STUDY; LIVER METABOLISM; LIVER TOXICITY; LUNG CANCER; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH ULCER; TREATMENT OUTCOME; TUMOR CELL LINE;

EID: 5444231928     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.5.725     Document Type: Review

References (82)

1. Surveillance Research - ACS. Lung and bronchus. In: Cancer Facts & Figures 2004. American Cancer Society, GA, USA, No. 5008-04 (2004).
2. Chesnutt MS, Prendergast TJ. Lung: pulmonary neoplasms. In: Current Medical Diagnosis and Treatment, 43rd Edition. Tierney LM Jr, McPhee SJ, Papadakis MA (Eds), Lang Medical Books/McGraw - Hill, NY, USA, 259-269 (2004).
3. Hollen PJ, Gralla RJ, Kris MG et al. Normative data and trends in quality of life from the lung cancer symptom scale (LCSS). Support. Care Cancer 7, 140 - 148 (1999).
4. Massarelli E, Andre F, Liu DD et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer 39, 55-61 (2003).
5. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy regimens. J. Clin. Oncol. 18, 2095-2103 (2003).
6. Fosella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 18, 2354-2362 (2000).
7. Kelloff GJ, Steele VE, Sigman CC. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. In: COX-2 Blockade in Cancer Prevention and Therapy. Harris RE (Ed.), Humana Press, NJ, USA, 279-300 (2003).
8. Mitchell JA, Akarasereenont P, Thiemermann C et al. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl Acad. Sci. 90, 11693-11697 (1994).
9. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol.) 231, 232-235 (1971).
10. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 13, 241-250 (1994).
11. DuBois RN, Awad J, Morrow J et al. Regulation of eicosanoids production and mitogenesis by transforming growth factor-β and phorbol ester. J. Clin. Investig. 93, 493-498 (1994).
12. O'Neill GP, Ford-Hutchison AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett.. 330, 156-160 (1993).
13. Needleman P, Isakson PC. The discovery and function of COX-2. J. Rheumatol. 24(Suppl. 49), 6-8 (1997).
14. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes 1 and 2. Ann. NY Acad. Sci. 14, 136-142 (1994).
15. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases 1 and 2: the mechanisms by which extracellular stimuli activate phospholipases are unresolved. Adv. Immunol. 62, 167-215 (1996).
16. Subbaramaiah K, Zakin D, Dannenberg A. Inhibition of cyclooxygenase; a novel approach to cancer prevention. Exp. Biol. Med. 216, 201-210 (1997).
17. Graul A, Martel AM, Castanar J. Celecoxib. Drugs Future 22, 711-714 (1999).
18. Weitzman SA, Gordon LI. Inflammation and cancer, role of phagocyte-generated oxidants in carcinogenesis. Blood 76, 655-663 (1990).
19. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58, 3761-3764 (1998).
20. Wolff H, Saukkonen K, Anttila S et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997-5001 (1998).
21. McLemore TL, Hubbard WE, Litterst CL et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 48, 3140-3147 (1988).
22. Hubbard WC, Alley MC, McLemore TL et al. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumors. Cancer Res. 48, 4770-4775 (1988).
23. El-Bayoumy K, Iatropoulos M, Amin S et al. Increased expression of cyclooxygenase-2 in rat lung tumor induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res. 59, 1400-1403 (1999).
24. Achiwa H, Yatabe Y, Hida Y et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary resected lung adenocarcinoma. Clin. Cancer Res. 5, 1001-1005 (1999).
25. Khuri FR, Wu H, Lee JJ et al. COX-2 overexpression is a marker of poor prognosis in Stage I non-small cell lung cancer. Clin. Cancer Res. 7, 861-867 (2001).
26. Hosomi Y, Yokose T, Hirose Y et al. Increased cyclooxygenase-2 expression occurs frequently in precursor lesions of human adenocarcinomas of lung. Lung Cancer 30, 73-81 (2000).
27. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs 8, 1623-1638 (1999).
28. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5, 138-146 (1994).
29. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol. Rep. 9, 693-695 (2002).
30. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18, 1001-1006 (1997).
31. Rious N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetyl salicylic acid and NS-398. Cancer Res. 58, 5354-5360 (1998).
32. Yao R, Rious N, Castonguay A. Inhibition of COX-2 and induction of apoptosis. Two determinants of non-steroidal anti-inflammatory drugs chemopreventive efficacy in mouse lung tumorigenesis. Exp. Lung Res. 26, 731-742 (2000).
33. Stolina M, Sharma S, Lin Y et al. Specific inhibition of cyclooxygenase-2 restore antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361-370 (2000).
34. Castonguay A, Rious N, Duperron C et al. Inhibition of lung tumorigenesis by NSAIDs. A working hypothesis. Exp. Lung Res. 24, 605-615 (1989).
35. Hida T, Kozaki KI, Muramatsu H. Cyclooxygenase-2 inhibitor induced apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6, 2006-2011 (2000).
36. Diperna CA, Bart RD, Sievers EM et al. Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J. Thorac. Cardiovasc. Surg. 126, 1129-1133 (2003).
37. Liu W, Chen Y, Wang W et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am. J. Clin. Oncol. 26(Suppl.), S103-S109 (2003).
38. Pyo H, Choy H, Amorino GP et al. A selective cyclooxygenase-2 inhibitor NS-398 enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 7, 2998-3005 (2001).
39. Hida T, Kozaki KI, Ito H. Significant growth inhibition of human lung cancer cells in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor JTE-522 and conventional anticancer agents. Clin. Cancer Res. 8, 2443-2447 (2002).
40. Milas L, Kishi K, Hunter N et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl Cancer Inst. 91, 1501-1504 (1999).
41. Kishi K, Peterson S, Peterson C et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60, 1326-1331 (2000).
42. Masferrer JL, Leahy KM, Koki AT. Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306-1311 (2000).
43. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Rad. Oncol. 11, 290-299 (2001).
44. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with complete resected Stage II or IIIA non-small cell lung cancer. N. Engl. J. Med. 343, 1217-1222 (2000).
45. Altorki NK, Kereszles RS, Port JL et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early stage non-small cell lung cancer. J. Clin. Oncol. 21, 2645-2650 (2003).
46. Carbone D, Choy H, Ciski I et al. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in Stage III non-small cell lung cancer (NSCLC: preliminary results of a Phase II trial. Proc. Am. Soc. Clin. Oncol. 21, 1270 (2002).
47. Gridelli C, Maione P, Airoma G et al. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr. Med. Chem. 9, 1851-1858 (2002).
48. Komaki R, Liao Z, Maas L. Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin. Oncol. 31 (Suppl. 1), 47-53 (2004).
49. Hubbard WC, Alley MC, Gray GN et al. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclass of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res. 49, 8266-8268 (1989).
50. Rose DP, Hatala AM, Connolly JM et al. Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in mice. Cancer Res. 53, 4686-4690 (1993).
51. Rose DP, Connolly JM. Stimulation of growth of human breast cancer lines in culture by linoleic acid. Biochem. Biophys. Res. Commun. 164, 277-283 (1989).
52. Tsujii M, Kawano S, Kawano S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716 (1998).
53. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors: a new class of antiangiogenic agents. Ann. NY Acad. Sci. 889, 84-86 (1999).
54. 2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95, 75-77 (1984).
55. McDougall CJ, Ngoi SS, Goldman IS et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res. 50, 8023-8027 (1990).
56. Shou M, Korzekwa KR, Krause KW et al. Specificity of cDNA-expressed human and rodent cytochrome P450 in the oxidative metabolism of the potent carcinogen 7,12-dimethyl benz(a)anthracene. Mol. Carcinog. 17, 241-249 (1996).
57. Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell 83, 493-501 (1995).
58. Grosch S, Tegeder I, Niederberger E et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15, 2742-2744 (2001).
59. Chan TA, Morin PJ, Vogelstein B et al. Mechanisms underlying non-steroidal anti-inflammatory drugs-mediated apoptosis. Proc. Natl Acad. Sci. USA 95, 681-686 (1998).
60. Tsujii M, Kawano S, Kawano S, DuBois RN. COX-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 94, 3336-33340 (1997).
61. 2 in human colon cancer cells. Cancer Res. 58, 362-366 (1998).
62. Liu X, Yao S, Kirschenbaum A et al. NS-398, a selective cyclooxygenase-2 inhibitor induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res. 58(19), 4245-4249 (1998).
63. He T-C, Chan TA, Vogelstein B et al. PPAR-γ is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell 99, 335-345 (1999).
64. Lin MT, Lee RC, Yang PC et al. Cyclooxygenase-2 inducing mcl-1 dependent survival mechanism in human lung adenocarcinoma CL10 cells. J. Biol. Chem. 276, 48997-49902 (2001).
65. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
66. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172, 214-218 (1983).
67. Jones MK, Wang H, Peskar PM et al. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs; insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med. 5, 1418-1423 (1999).
68. Hanif R, Pittas A, Feng Y et al. Effects of NSAIDs on proliferation and induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52, 237-245 (1996).
69. Piazza GA, Rahm AL, Krutsch MI et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55, 3110-3116 (1995).
70. Duggan DE, Hare LE, Ditzler GA et al. The disposition of sulindac. Clin. Pharmacol. Ther. 21, 236-335 (1977).
71. Shiff SJ, Rigas B. The role of cyclooxegenase inhibition in the antineoplastic effects of NSAIDs. J. Exp. Med. 190, 445-450 (1999).
72. Isakson P, Zweifel B, Masferrer J et al. Specific COX-2 inhibitors from bench to bedside. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Vane J, Botting J (Eds), William Harvey Press, London, UK, 127-133 (1997).
73. Brooks PM, Day RD. COX-2 inhibitors. Med. J. Aust. 173, 433-436 (2000).
74. Penning TD, Talley JJ, Bertenshaw SR et al. Synthesis and biological evaluation of the 1,5-diaryl pyrazole class of cyclooxygenase-2 inhibitors. J. Med. Chem 40, 1347-1365(1997).
75. Pamham MJ. Inflammation, mechanisms and therapeutics. Drugs New Perspect. 9, 631-639 (1996).
76. Lanza FL, Rack MF. A pilot endoscopy, study of the gastro duodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology 112, A194 (1997).
77. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel COX-2 selective inhibitor; efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 41, 1591-1602 (1998).
78. Mengle-Gaw L, Hubbard RC, Karim A et al. A study of the platelet effect of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheum. 40 (Suppl.), S93 (1997).
79. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study; a randomized controlled trial. JAMA 284, 1247-1255 (2000).
80. Simon LS, Weaver AL, Graham AY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 282, 1921-1928 (1999).
81. Emery P, Zeidler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 354, 2106-2111 (1999).
82. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 432, 1946-1952 (2000).